A carregar...
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial
The vasopressin–cAMP–osmolality axis is abnormal in autosomal dominant polycystic kidney disease (ADPKD). In the Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 Trial, a 3-year randomized, placebo-controlled trial in adults, the vasopr...
Na minha lista:
Publicado no: | J Am Soc Nephrol |
---|---|
Main Authors: | , , , , , , , , , |
Formato: | Artigo |
Idioma: | Inglês |
Publicado em: |
American Society of Nephrology
2017
|
Assuntos: | |
Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5407721/ https://ncbi.nlm.nih.gov/pubmed/27920153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2016040448 |
Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|
A carregar...